SAN DIEGO, September 9, 2017 – ProSciento Inc., metabolism-focused, full scope clinical R&D services provider, will present study results at this week’s at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, September 11-15 in Lisbon.
Poster and oral presentations co-authored by ProSciento scientists include:
The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers
ePoster #864 (link to abstract)
Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects
Oral Presentation #110 (link to abstract)
MEDI4166, a novel antibody (PCSK9)-peptide (GLP-1) fusion molecule: single-ascending-dose study in patients with type 2 diabetes
Abstract #114 (link to abstract)
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427